Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa
Abstract Objective We aimed to compare clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to infer the lineage/variant causing infection.Methods We included public sector patients aged ≥20 years with laboratory-confirmed COVID-19 between 1-21 May 2022 (BA.4/BA.5 wave) and equivalent prior wave periods. We compared the risk between waves of (i) death and (ii) severe hospitalization/death (all within 21 days of diagnosis) using Cox regression adjusted for demographics, comorbidities, admission pressure, vaccination and prior infection.Results Among 3,793 patients from the BA.4/BA.5 wave and 190,836 patients from previous waves the risk of severe hospitalization/death was similar in the BA.4/BA.5 and BA.1 waves (adjusted hazard ratio (aHR) 1.01; 95% confidence interval (CI) 0.92; 1.12). Both Omicron waves had lower risk of severe outcomes than previous waves. Prior infection (aHR 0.19, 95% CI 0.16; 0.22) and vaccination (aHR 0.24; 95% CI 0.15; 0.39 for boosted vs. no vaccine) were protective.Conclusion Disease severity was similar amongst diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 due to prior infection and vaccination, both of which were strongly protective..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Davies, Mary-Ann [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.06.28.22276983 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI036404624 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI036404624 | ||
| 003 | DE-627 | ||
| 005 | 20240425104219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220701s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.06.28.22276983 |2 doi | |
| 035 | |a (DE-627)XBI036404624 | ||
| 035 | |a (biorXiv)10.1101/2022.06.28.22276983 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Davies, Mary-Ann |e verfasserin |0 (orcid)0000-0001-8496-6475 |4 aut | |
| 245 | 1 | 0 | |a Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Objective We aimed to compare clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to infer the lineage/variant causing infection.Methods We included public sector patients aged ≥20 years with laboratory-confirmed COVID-19 between 1-21 May 2022 (BA.4/BA.5 wave) and equivalent prior wave periods. We compared the risk between waves of (i) death and (ii) severe hospitalization/death (all within 21 days of diagnosis) using Cox regression adjusted for demographics, comorbidities, admission pressure, vaccination and prior infection.Results Among 3,793 patients from the BA.4/BA.5 wave and 190,836 patients from previous waves the risk of severe hospitalization/death was similar in the BA.4/BA.5 and BA.1 waves (adjusted hazard ratio (aHR) 1.01; 95% confidence interval (CI) 0.92; 1.12). Both Omicron waves had lower risk of severe outcomes than previous waves. Prior infection (aHR 0.19, 95% CI 0.16; 0.22) and vaccination (aHR 0.24; 95% CI 0.15; 0.39 for boosted vs. no vaccine) were protective.Conclusion Disease severity was similar amongst diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 due to prior infection and vaccination, both of which were strongly protective. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Morden, Erna |e verfasserin |4 aut | |
| 700 | 1 | |a Rosseau, Petro |e verfasserin |4 aut | |
| 700 | 1 | |a Arendse, Juanita |e verfasserin |4 aut | |
| 700 | 1 | |a Bam, Jamy-Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Boloko, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Cloete, Keith |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Cheryl |e verfasserin |4 aut | |
| 700 | 1 | |a Chetty, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Dane, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Heekes, Alexa |e verfasserin |4 aut | |
| 700 | 1 | |a Hsiao, Nei-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Hunter, Mehreen |e verfasserin |4 aut | |
| 700 | 1 | |a Hussey, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, Theuns |e verfasserin |4 aut | |
| 700 | 1 | |a Jassat, Waasila |e verfasserin |4 aut | |
| 700 | 1 | |a Kariem, Saadiq |e verfasserin |4 aut | |
| 700 | 1 | |a Kassanjee, Reshma |e verfasserin |4 aut | |
| 700 | 1 | |a Laenen, Inneke |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, Sue Le |e verfasserin |4 aut | |
| 700 | 1 | |a Lessells, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Mahomed, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Maughan, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Meintjes, Graeme |e verfasserin |4 aut | |
| 700 | 1 | |a Mendelson, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Mnguni, Ayanda |e verfasserin |4 aut | |
| 700 | 1 | |a Moodley, Melvin |e verfasserin |4 aut | |
| 700 | 1 | |a Murie, Katy |e verfasserin |4 aut | |
| 700 | 1 | |a Naude, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Ntusi, Ntobeko A. B. |e verfasserin |4 aut | |
| 700 | 1 | |a Paleker, Masudah |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Arifa |e verfasserin |4 aut | |
| 700 | 1 | |a Pienaar, David |e verfasserin |4 aut | |
| 700 | 1 | |a Preiser, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Prozesky, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Raubenheimer, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Rossouw, Liezel |e verfasserin |4 aut | |
| 700 | 1 | |a Schrueder, Neshaad |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Barry |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Mariette |e verfasserin |4 aut | |
| 700 | 1 | |a Solomon, Wesley |e verfasserin |4 aut | |
| 700 | 1 | |a Symons, Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Taljaard, Jantjie |e verfasserin |4 aut | |
| 700 | 1 | |a Wasserman, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkinson, Robert J. |e verfasserin |4 aut | |
| 700 | 1 | |a Wolmarans, Milani |e verfasserin |4 aut | |
| 700 | 1 | |a Wolter, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Boulle, Andrew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2022.11.024 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.06.28.22276983 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||